期刊文献+

硼替佐米治疗淋巴瘤的疗效分析 被引量:2

下载PDF
导出
摘要 目的对非霍奇金淋巴瘤使用硼替佐米进行治疗的临床效果进行观察。方法共5例非霍奇金淋巴瘤患者,使用硼替佐米进行两个疗程的联合化疗,依据国际淋巴瘤治疗标准对临床治疗效果进行判断,记录患者治疗后出现的不良反应。结果全部患者中,1例患者病情得到完全缓解,其余4例患者的病情得到部分的缓解。治疗后出现的不良反应有:3例患者出现乏力,4例患者的血小板数量发生减少,4例患者胃肠道出现刺激反应,2例患者发生神经病变,经过及时治疗均得到缓解。结论非霍奇金淋巴瘤患者使用硼替佐米联合化疗的方式进行治疗,能够取得很好的临床效果。
作者 王子峰
出处 《中国医学工程》 2013年第5期60-61,共2页 China Medical Engineering
  • 相关文献

参考文献3

二级参考文献30

  • 1Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells[J]. Proc Natl Acad Sci USA,2002,99(22). 14374-14379.
  • 2Paoluzzi L, O'Connor OA. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas[J]. Bio Drugs,2006,20 (1):13-23.
  • 3Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitorbortezomib in relapsed or refractory B-cell non-hodgkin's lymphoma[J]. Journal of Clinical Oncology, 2005,23(4):667-675.
  • 4O'Connor OA, Wright J, Moskowitz C, et al. Phase Ⅱ clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-hodgkin's lymphoma and mantle cell lymphoma[J]. Journal of Clinical Oncology, 2005,23(4):676-684.
  • 5Goy A, Hart S, Pro B, et al. Report of a phase Ⅱ study ofproteasome inhibitor bortezomib (Velcade) in patients with relapsed or refractory indolent or aggressive lymphoma[J]. Blood, 2003,1020:627.
  • 6Fisher RI, Bernstein SH, Kahl BS,et al. Multicenter phase Ⅱstudy of bortezomib in patients with relapsed or refractory mantle cell lymphoma [J]. Journal of Clinical Oncology, 2006,24 (30):4867-4874.
  • 7Koc ON, Bahlis N J, Liu L, et al. A phase I trial of bortezomib in combination with fludarabine in patients with lymphoproliferative neoplasms[J]. Journal of Clinical Oncology, 2005,23(16):6647.
  • 8Dunleavy K, Janik J, Gea-Banacloche J, et al. Phase Ⅰ/Ⅱ study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refraclory aggressive B-cell lymphoma[J]. Blood (ASH Annual Meeting Abstracts) ,2004,104(9): 1385-1392.
  • 9De Vos S, Dakhil S, McLaughlin P, et al. Bortezomib plus rituximab in patients with indolent non-hodgkin' s lymphoma (NHL): a phase 2 study[J]. Blood (ASH Annuzd Meeting Abstracts), 2005,106:17.
  • 10Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies[J]. Blood,2005,105 (8):3058-3065.

共引文献1

同被引文献6

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部